Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (39)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kremer, L. C. M.
Right arrow Articles by Voûte, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kremer, L. C. M.
Right arrow Articles by Voûte, P. A.
Related Collections
Right arrow 2002 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:503-512, 2002
© 2002 European Society for Medical Oncology

Review Article

Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review

L. C. M. Kremer1,+, E. C. van Dalen2, M. Offringa2 and P. A. Voûte1

Departments of 1Pediatric Oncology and 2Pediatrics, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

Received 28 June 2001; revised 2 November 2001; accepted 16 November 2001.

Abstract

Background

Anthracyclines are essential for the treatment of the children with cancer. We performed a systematic review to evaluate the existing evidence of the frequency and risk factors of anthracycline-induced clinical heart failure (A-CHF) in children.

Design

Medline was searched for articles reporting the frequency of A-CHF, published from 1966 to December 2000. Information about study features, risk factors and frequency were abstracted, and a validity score was given for each study. The potential predictive factors of A-CHF were analysed both within and across the studies.

Results

The frequency of A-CHF in children was estimated in 30 studies described in 25 articles. All studies have serious methodological limitations. The frequency varied between 0% and 16%. In the analysis across the studies the type of anthracyclines and the maximal dose in 1 week explain a considerable part of the variation of the frequency of A-CHF.

Conclusions

Doxorubicin and a dose above 45 mg/m2 within 1 week seemed to increase the frequency of A-CHF. Well designed and executed studies are needed to accurately estimate the frequency of A-CHF and reliably assess the importance of potential risk factors.

Key words: anthracycline, cardiotoxicity, children, heart failure, systematic review


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
P. C. Nathan, M. L. Greenberg, K. K. Ness, M. M. Hudson, A. C. Mertens, M. C. Mahoney, J. G. Gurney, S. S. Donaldson, W. M. Leisenring, L. L. Robison, et al.
Medical Care in Long-Term Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study
J. Clin. Oncol., September 20, 2008; 26(27): 4401 - 4409.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. Carter, W. Landier, A. Schad, A. Moser, A. Schaible, C. Hanby, S. Kurian, F. L. Wong, D. Villaluna, and S. Bhatia
Successful Coordination and Execution of Nontherapeutic Studies in a Cooperative Group Setting: Lessons Learned from Children's Oncology Group Studies
Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1665 - 1673.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
E. C. van Dalen and L. C. M. Kremer
Effect of Dosing Schedules on Anthracycline-induced Cardiotoxicity in Children with Cancer
ASCO Educational Book, January 1, 2008; 2008(1): 442 - 447.
[Abstract] [Full Text] [PDF]

Home page
 AAP Grand RoundsHome page
A. D. Villella
Monitoring Survivors of Childhood AML for Anthracycline Cardiotoxicity
AAP Grand Rounds, December 1, 2007; 18(6): 62 - 63.
[Full Text] [PDF]

Home page
 JCOHome page
M. M. Hudson, S. N. Rai, C. Nunez, T. E. Merchant, N. M. Marina, N. Zalamea, C. Cox, S. Phipps, R. Pompeu, and D. Rosenthal
Noninvasive Evaluation of Late Anthracycline Cardiac Toxicity in Childhood Cancer Survivors
J. Clin. Oncol., August 20, 2007; 25(24): 3635 - 3643.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
J. A. Hayden, P. Cote, and C. Bombardier
Evaluation of the quality of prognosis studies in systematic reviews.
Ann Intern Med, March 21, 2006; 144(6): 427 - 437.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. Cardinale, M. T. Sandri, A. Colombo, N. Colombo, M. Boeri, G. Lamantia, M. Civelli, F. Peccatori, G. Martinelli, C. Fiorentini, et al.
Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy
Circulation, June 8, 2004; 109(22): 2749 - 2754.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.